Max Wang

DAS181 is a first-in-class host-directed recombinant sialidase protein derived from Actinomyces viscosus (av). It was designed to remove sialic acids located on the surface of epithelial cells lining the human respiratory tract. These sialic acids are naturally present on cell surfaces and are needed by many viruses, including influenza, parainfluenza, and enterovirus D68, for entry into cells. Cleavage of sialic acid on the patient’s respiratory epithelial cells may block viral entry, and provide a host-directed mechanism to treat respiratory viral infections. Ansun is currently enrolling eligible patients in STOP-PIV (DAS181-3-01), a Phase 3 study of DAS181 treatment of lower respiratory tract parainfluenza infection (PIV) in immunocompromised patients (ClinicalTrials.gov Identifier: NCT03808922). Ansun looks for global pharma partners to develop DAS181 to fight respiratory infectious diseases.

A global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing.

HJB was founded by senior experts from world-famous pharmaceutical companies including Amgen and is now a company of Transcenta Holding. HJB is dedicated to designing and applying advanced continuous process for monoclonal antibodies using innovative technologies and platforms. Combined with the flexible POD-based manufacturing facility that enables mass production, HJB is able to dramatically increase the output and quality of these biologics that meet international standards, while at the same time significantly accelerating R&D process and reduce manufacturing cost. HJB has established R&D Center and GMP Manufacturing in Hangzhou, China and External Partnering Center in Boston, US.

• Achieved high growth in account number and in revenue in the region responsible for. • Negotiated and signed contracts in including scopes from mAb discovery to integrated CMC and MFG. • Account management effort lead to innovative business model and multi-million dollar contracts. • Collaborated with internal management team and technical team and redefined and improved lead triage process, proposal drafting process and pricing structure. • Trained sales specialist in a segment to achieve over 100% annual growth.

• Achieved high level growth in the market segment responsible for. • Negotiated and signed contracts antibody discovery and pre-clinical development stages. • Performed market research, designed and executed life science incubator analysis, led to leads and high value proposals. • Evaluated discovery service market demand and competitive landscape and accordingly adjusted key offering.

Worked with emerging entrepreneurs on developing a business plan for the start-up. Interacted with seasoned industry professionals from pharma, biotech business development and corporate strategics groups, marketing and finance professionals, VC’s, IP attorney.

• Reviewed literature and databases and delivered industry trend and competitive landscape reports to facilitate evaluation of market potential and feasibility of technologies. • Participated in a technology project which was selected by the university as candidate platform of fundraising. • Led the team in a pharmaceutical and personalized medicine project and shaped actionable business plan for university tech transfer office. • Redesigned B2B marketing strategy to focus on brand positioning and sales team operation for a Fortune 150 company.

Membrane protein biogenesis